GlassScriptPhysician profile
Nicole Rierson
NPI 1942935713
$3,139.95
in general payments reported to CMS, 2019-2025
26 companies · $792 in 2025
The $792 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $182 · 2023: $659 · 2024: $1,507 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.47 | 2023-2024 | Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $297.32 | 2022-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $253.95 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $251.87 | 2022-2025 | Dupixent |
| United Therapeutics Corporation | $193.22 | 2024-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $191.99 | 2022-2025 | Glassia, Hyqvia |
| Genzyme Corporation | $183.28 | 2023-2025 | |
| Mylan Specialty L.P. | $160.68 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $126.02 | 2023-2024 | Uptravi, Opsumit |
| Verona Pharma, INC. | $121.23 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $110.06 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Mallinckrodt Hospital Products INC. | $94.83 | 2023-2025 | Acthar |
| Vifor Pharma, INC. | $93.92 | 2024 | Veltassa, Zemaira |
| Insmed, INC. | $84.02 | 2023-2024 | Arikayce |
| Avadel Cns Pharmaceuticals, LLC | $66.12 | 2024-2025 | Lumryz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $63.19 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Shionogi INC | $56.06 | 2022-2024 | Fetroja |
| Philips North America LLC | $49.39 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Harmony Biosciences LLC | $47.49 | 2025 | |
| Amgen INC. | $36.43 | 2022-2024 | Tavneos |
| Boston Scientific Corporation | $32.49 | 2024-2025 | Avvigo Guidance System |
| Inari Medical, INC. | $29.95 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Viatris Specialty LLC | $23.86 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $18.85 | 2022 | |
| Medtronic, INC. | $18.28 | 2024 | Valiant Captivia |
| La Jolla Pharmaceutical Company | $17.98 | 2025 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Rierson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.